FAP and sarcoma: Until now, FAP-RLT has been tested preclinically in many immunocompromised xenograft models like human HT1080-FAP [24], HEK293-FAP and patient-derived sarcoma [25], as well as in human PANC-1 and MIA PaCa-2 xenografts [26, 27].